Grace Therapeutics
GRCE
10 hedge funds and large institutions have $721K invested in Grace Therapeutics in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and closing their positions.
0.1% more ownership
Funds ownership: 0% → 0.1% (+0.1%)
0% more funds holding
Funds holding: 10 → 10 (0)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
32% less capital invested
Capital invested by funds: $1.05M → $721K (-$334K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$13.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$3.16K |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
+$336 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$69.9K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$9.33K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.36K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$470 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Bank of Montreal
Toronto,
Ontario, Canada
| $245K | -$3.36K | -50 | -1% |
|
|
PA
2
Perceptive Advisors
New York
| $233K | -$69.9K | -1,041 | -21% |
|
|
IIM
3
Intact Investment Management
Montreal,
Quebec, Canada
| $154K | – | – | – |
|
|
4
Renaissance Technologies
New York
| $56K | +$13.4K | +200 | +27% |
|
|
VKH
5
Virtu KCG Holdings
New York
| $28K | -$9.33K | -139 | -23% |
|
|
6
UBS Group
Zurich,
Switzerland
| $4K | +$3.16K | +47 | +214% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $1K | -$470 | -7 | -54% |
|
|
8
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | +$336 | +5 | +500% |
|
GRCE Hedge Fund Activity: Q4 2016 in Review
10 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q4 2016, worth a combined $721K — down 32% from $1.05M a quarter earlier.
Fund positioning in GRCE was balanced in Q4 2016: 0 funds opened new positions, 0 closed out, 3 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $13.4K. The largest seller was Perceptive Advisors, cutting an estimated $69.9K.
- 10 institutional investors held Grace Therapeutics (GRCE) as of Q4 2016, unchanged from Q3 2016.
- Funds reported $721K of Grace Therapeutics stock for Q4 2016, down 32% quarter-over-quarter.
- 0 funds opened new Grace Therapeutics positions in Q4 2016 and 0 closed out.
- The largest Grace Therapeutics buyer in Q4 2016 was Renaissance Technologies, an estimated $13.4K added.
- The largest Grace Therapeutics seller in Q4 2016 was Perceptive Advisors, an estimated $69.9K sold.
Based on aggregated 13F filings for Q4 2016.